GSK: two-drug HIV regimen show encouraging long-term results
(CercleFinance.com) - GSK's ViiV Healthcare said three-year data for a investigational long-acting injectable, two-drug HIV regimen showed high rates of virologic response and long-term durability over 160 weeks.
At 160 weeks, 90% and 83% of the patients receiving an injectable regimen of cabotegravir and rilpivirine every eight and four weeks, respectively, remained virally suppressed, according to the phase II results.
The two-drug HIV regimen of cabotegravir and rilpivirine is intended to provide an alternative to daily pills, reducing the number of annual doses from 365 to 12.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
At 160 weeks, 90% and 83% of the patients receiving an injectable regimen of cabotegravir and rilpivirine every eight and four weeks, respectively, remained virally suppressed, according to the phase II results.
The two-drug HIV regimen of cabotegravir and rilpivirine is intended to provide an alternative to daily pills, reducing the number of annual doses from 365 to 12.
Copyright (c) 2018 CercleFinance.com. All rights reserved.